Skip to main content
Toggle navigation
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Red Recording
Sig Meeting
Like
Tweet
Print
Natty Chalermpalanupap, PhD
AbbVie Inc., North Chicago, IL, USA
Poster(s):
(E 55) Real-World Migraine Treatment Patterns in the Era of CGRP-Targeted Therapies: Low Preventive Uptake and Dynamic Regimen Shifts: A Retrospective Claims Analysis
(E 61) Migraine in America Symptoms and Treatment (MAST) Study: A Subgroup Analysis of Women with Perimenstrual Headache (MAST-MM)
(T 25) Consistency of Ubrogepant for the Acute Treatment of Migraine Across Consecutive Migraine Attacks: Results from a 52-Week Long-Term Extension Trial
(T 40) Ubrogepant Efficacy Based on Historical Cutaneous Allodynia and Triptan Response: Results from the PRODROME Trial
(T 41) Efficacy of Ubrogepant 100 mg Based on Prior Triptan Experience: Results From the ACHIEVE I Study
(CP 06) Migraine in America Symptoms and Treatment (MAST) Study: Evaluating Burden and Disability in a Subgroup of Women with Perimenstrual Headache (MAST-MM)
